# Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

Source: https://onco.cc/trials/nct06686030/  
OnCo record `nct06686030` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ivonescimab, Olaparib in ovarian cancer, run by Akeso, now recruiting.

## Summary

Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer is a phase 2 interventional study registered as NCT06686030 by Akeso, with 150 participants planned, started 2025-02-17 and due to reach its primary completion in 2027-10. Interventions recorded: AK112 low dose, Chemotherapy, Olaparib, AK112 high dose. Conditions listed: Platinum-sensitive Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06686030
- Phase: 2
- Setting: An Exploratory, Multi-cohort Phase II Study of Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer
- Sponsor: Akeso
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT06686030: https://clinicaltrials.gov/study/NCT06686030

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Olaparib](https://onco.cc/drugs/olaparib/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct06686030.json